RPRX Stock Summary and Trading Ideas (Royalty Pharma PLC - Class A | NASDAQ:RPRX)

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Royalty Pharma PLC - Class A trades on the NASDAQ stock market under the symbol RPRX.

As of March 26, 2026, RPRX stock price declined to $46.94 with 2,835,310 million shares trading.

RPRX has a beta of 0.37, meaning it tends to be less sensitive to market movements. RPRX has a correlation of 0.13 to the broad based SPY ETF.

RPRX has a market cap of $20.11 billion. This is considered a Large Cap stock.

Last quarter Royalty Pharma PLC - Class A reported $622 million in Revenue and $1.47 earnings per share. This fell short of revenue expectation by $-211 million and exceeded earnings estimates by $.14.

In the last 3 years, RPRX traded as high as $47.86 and as low as $24.05.

The top ETF exchange traded funds that RPRX belongs to (by Net Assets): VXF, VFLO, VYM, IWR, SCHM.

RPRX has outperformed the market in the last year with a price return of +41.7% while the SPY ETF gained +13.4%. RPRX has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +20.2% and +0.5%, respectively, while the SPY returned -6.3% and -4.4%, respectively.

RPRX support price is $46.28 and resistance is $47.78 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RPRX shares will trade within this expected range on the day.